Back
ESC Professional Premium Access

Interrelation between baseline plaque characteristics and changes in coronary atherosclerosis with the PCSK9-inhibitor alirocumab: Insights from the PACMAN-AMI randomized trial

Session: Lipid-lowering therapy and the atheroma
Topic: Angiography, Invasive Imaging
Speaker: Doctor K. Koskinas (Bern, CH)
Event: ESC Congress 2022

Congress Presentation

Add to my library

Like

About the speaker

Doctor Konstantinos Koskinas

Bern University Hospital, Inselspital, Bern (Switzerland)
17 presentations
25 followers

2 more presentations in this session

State-of-the-art lecture in lipid lowering therapy and the atheroma .

Speaker: Professor S. Nicholls (Melbourne, AU)

Access
Slides
Video
Like
Thumbnail

Longer-term safety of alirocumab with 24,610 patient-years of placebo-controlled observation: Further insights from the ODYSSEY OUTCOMES trial

Speaker: Doctor S. Goodman (Toronto, CA)

Access
Abstract
Slides
Video
Like
Thumbnail

Access the full session

Lipid-lowering therapy and the atheroma

Speakers: Doctor K. Koskinas, Professor S. Nicholls, Doctor S. Goodman
Access
Video
Like
Thumbnail

About the event

Image

ESC Congress 2022

26 August - 29 August 2022

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

logo Bristol Myers Squibb Explore sponsored resources
logo Novo Nordisk Explore sponsored resources